Biomarkers in the Evaluation of Chronic Lung Disease

Completed

Conditions studied: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease

In brief

We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.

Key facts

Study ID

NCT00926523

Run by

Northwell Health

People needed

67

Starts

2009-06-01

Expected to finish

2011-03-01

Last updated by the study team

2011-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subject are at least 18 years of age
• Subject has confirmed Pulmonary Hypertension and Interstitial Lung Disease
• Subject are able to complete study procedures, such as spirometry, and Pulmonary Exercise test.

You may not qualify if…

• Subject are pregnant
• Subject is unable to perform tasks associated with study

Where it is running

• Interstitial Lung Disease and Pulmonary Hypertension Programs — New Hyde Park, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.